DK1313511T3 - Testosteronesterformulering til human brug - Google Patents

Testosteronesterformulering til human brug

Info

Publication number
DK1313511T3
DK1313511T3 DK01971928T DK01971928T DK1313511T3 DK 1313511 T3 DK1313511 T3 DK 1313511T3 DK 01971928 T DK01971928 T DK 01971928T DK 01971928 T DK01971928 T DK 01971928T DK 1313511 T3 DK1313511 T3 DK 1313511T3
Authority
DK
Denmark
Prior art keywords
testosterone
human use
testosterone ester
ester formulation
formulation
Prior art date
Application number
DK01971928T
Other languages
Danish (da)
English (en)
Inventor
Nijs Henrik De
Wendy Margaretha Kersemaekers
Bruggen Johann Gerhard Cor Van
Sephanus Cornelis Schutte
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Application granted granted Critical
Publication of DK1313511T3 publication Critical patent/DK1313511T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
DK01971928T 2000-08-23 2001-08-17 Testosteronesterformulering til human brug DK1313511T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00202939 2000-08-23

Publications (1)

Publication Number Publication Date
DK1313511T3 true DK1313511T3 (da) 2006-03-20

Family

ID=8171940

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01971928T DK1313511T3 (da) 2000-08-23 2001-08-17 Testosteronesterformulering til human brug

Country Status (15)

Country Link
US (1) US20050101517A1 (el)
EP (1) EP1313511B1 (el)
JP (1) JP2004506698A (el)
CN (1) CN1248738C (el)
AT (1) ATE311201T1 (el)
AU (2) AU9177501A (el)
BR (1) BR0113376A (el)
CA (1) CA2415349A1 (el)
CY (1) CY1106064T1 (el)
DE (1) DE60115464T2 (el)
DK (1) DK1313511T3 (el)
ES (1) ES2253423T3 (el)
IL (2) IL153648A0 (el)
MX (1) MXPA03001147A (el)
WO (1) WO2002015938A2 (el)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200404552A (en) * 2002-05-30 2004-04-01 Akzo Nobel Nv Self administered contraception
JO2505B1 (en) 2003-03-14 2009-10-05 باير شيرنغ فارما اكتنجيسيلشافت Pharmacy methods and formulations for obtaining acceptable serum testosterone levels
IL157535A0 (en) * 2003-08-21 2004-03-28 Topimed Ltd Preparations for the prevention of skin atrophy
US8541413B2 (en) * 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
EP2452670A1 (en) * 2004-10-01 2012-05-16 Ramscor, Inc. Conveniently implantable sustained release drug compositions
US20080038316A1 (en) * 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
US9993558B2 (en) 2004-10-01 2018-06-12 Ramscor, Inc. Sustained release eye drop formulations
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
AU2006236564B2 (en) 2005-04-15 2011-02-17 Tolmar, Inc. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
PL2519230T3 (pl) 2009-12-31 2019-05-31 Marius Pharmaceuticals Llc Modulacja rozpuszczalności, stabilności, absorpcji, metabolizmu i profilu farmakokinetycznego leków lipofilowych przez sterole
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
TW201521731A (zh) * 2013-03-15 2015-06-16 利波辛股份有限公司 用於口服之脂平衡的長鏈睪固酮酯
EP2968137B1 (en) 2013-03-15 2021-11-10 Marius Pharmaceuticals LLC Emulsion formulations
US10245273B2 (en) 2013-12-26 2019-04-02 Clarus Therapeutics, Inc. Oral pharmaceutical products and methods of use combining testosterone esters with hypolipidemic agents
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2018064556A1 (en) 2016-09-29 2018-04-05 Gesea Biosciences Inc. Bioerodible implant for long-term drug delivery and associated methods of manufacture and use
CA3078723A1 (en) 2016-11-28 2018-05-31 Nachiappan Chidambaram Oral testosterone undecanoate therapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB465331A (en) * 1935-10-05 1937-05-05 Chem Ind Basel Manufacture of new esters of polynuclear cyclic oxyketones
NL189235C (nl) * 1974-02-28 1993-02-16 Akzo Nv Werkwijze voor de bereiding van een oraal toe te dienen farmaceutisch preparaat met androgene werking.
US4098802A (en) * 1975-02-18 1978-07-04 Akzona Incorporated Oral pharmaceutical preparation having androgenic activity
US4147783A (en) * 1974-02-28 1979-04-03 Akzona Incorporated Oral pharmaceutical preparation
NL7506407A (nl) * 1975-05-30 1976-12-02 Akzo Nv Werkwijze ter bereiding van een oraal werkzaam far- maceutisch preparaat.
GB1567515A (en) * 1976-05-28 1980-05-14 Akzo Nv Esters of testo-sterone and 5 -dihydro-testosterone
ATE86484T1 (de) * 1987-08-08 1993-03-15 Akzo Nv Kontrazeptives implantat.
US6063395A (en) * 1998-11-12 2000-05-16 Leiras Oy Drug delivery device especially for the delivery of progestins and estrogens
US7025979B2 (en) * 2000-02-15 2006-04-11 Schering Ag Male contraceptive formulation comprising norethisterone

Also Published As

Publication number Publication date
ATE311201T1 (de) 2005-12-15
CA2415349A1 (en) 2002-02-28
EP1313511B1 (en) 2005-11-30
US20050101517A1 (en) 2005-05-12
AU9177501A (en) 2002-03-04
DE60115464T2 (de) 2006-06-14
AU2001291775B2 (en) 2005-09-08
WO2002015938A3 (en) 2002-08-15
DE60115464D1 (de) 2006-01-05
WO2002015938A2 (en) 2002-02-28
JP2004506698A (ja) 2004-03-04
CN1248738C (zh) 2006-04-05
IL153648A (en) 2009-02-11
MXPA03001147A (es) 2003-10-06
EP1313511A2 (en) 2003-05-28
IL153648A0 (en) 2003-07-06
CN1443078A (zh) 2003-09-17
BR0113376A (pt) 2003-07-15
CY1106064T1 (el) 2011-06-08
ES2253423T3 (es) 2006-06-01
WO2002015938A8 (en) 2004-03-04

Similar Documents

Publication Publication Date Title
DK1313511T3 (da) Testosteronesterformulering til human brug
DE59911740D1 (de) Topisch anwendbare mittel gegen nagelpilzerkrankungen
TW200509983A (en) The dermal external agent for inhibiting or repairing the dermal damage due to drying
AU2003297260A1 (en) Fast-disintegrating solid dosage forms being not friable and comprising pullulan
MY138883A (en) Use of asiatic acid for treatment of cencer
DE60105448D1 (de) Feste dispersionen mit nitrataktiven wirkstoffen
ATE367087T1 (de) Formulierungen zur behandlung von krankheiten und verfahren unter deren verwendung
ATE314084T1 (de) Kahalalid f formulierung
ATE301999T1 (de) Racecadotril enthaltende trockene pulverformulierung
NO20023102L (no) Fremgangsmåte og formulering for behandling av residens mot anti-hypertensiver og relaterte tilstander
NZ522242A (en) Use of 13-hode as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
ZA200502613B (en) Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents
WO2004052294A3 (en) Compositions and methods related to lipid:emodin formulations
IL138290A0 (en) Use of selegiline or desmethylselegiline for treating wounds, burns and dermatological damage
NZ528164A (en) Use of flumazenil to produce a medicament for the treatment of ***e dependency
AU2001255801A1 (en) Neutralization of phosphate esters, compositions based upon and methods using same
EE200300057A (et) Koostis vähi profülaktikaks ja raviks
HUP0301451A3 (en) Use of cgmp pde5 inhibitors for the preparation of pharmaceutical compositions treating peripheral vascular diseases, peripheral neuropathies and autonomic neuropathies
AR034606A1 (es) Composiciones cosmeticas
JP2003119489A5 (ja) 香料成分としての第三アルコールまたはエステルの使用
ATE327727T1 (de) Hautpflegemittel
NO20031080L (no) Fettsyreanaloger for behandling av proliferative sykdommer
NZ504525A (en) Use of cetyl alcohol esters of myristic and palmitic acids to treat eczema and psoriasis
MD1580G2 (ro) Agent antimutagen
GB0209376D0 (en) Compositions for the treatment of wounds and damaged dermal tissue